ETF Series Solutions - Range Cancer Therapeutics ETF (NASDAQ: CNCR)
Some price data may be temporarily unavailable.
ETF Series Solutions - Range Cancer Therapeutics ETF Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ETF Series Solutions - Range Cancer Therapeutics ETF Company Info
Loncar Cancer Immunotherapy ETF
News & Analysis
Featured Article
3 Index Funds to Buy in August
Our contributors take a look at three index funds in promising areas such as emerging markets, cancer immunotherapy, and banks.
Andrés Cardenal, Jason Hall, and George Budwell | Aug 1, 2016
Featured Article
3 High-Growth ETFs to Supercharge Your Portfolio
Exposing your portfolio to high-growth industries while staying diversified is a way to boost your portfolio with less risk.
Cory Renauer, Matt Frankel, and Brian Feroldi | Jun 1, 2016
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.